GAMMA Investing LLC Purchases 31,343 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

GAMMA Investing LLC increased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1,465.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,482 shares of the company’s stock after acquiring an additional 31,343 shares during the quarter. GAMMA Investing LLC’s holdings in Genmab A/S were worth $656,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc increased its holdings in shares of Genmab A/S by 1,108.3% during the 1st quarter. Versant Capital Management Inc now owns 8,724 shares of the company’s stock worth $171,000 after purchasing an additional 8,002 shares during the period. Marotta Asset Management increased its stake in Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company’s stock valued at $265,000 after acquiring an additional 739 shares during the period. Employees Retirement System of Texas bought a new stake in Genmab A/S in the fourth quarter valued at about $1,648,000. Mackenzie Financial Corp bought a new stake in Genmab A/S in the fourth quarter valued at about $689,000. Finally, GTS Securities LLC bought a new stake in Genmab A/S in the fourth quarter valued at about $1,552,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 2.1%

Shares of Genmab A/S stock opened at $21.56 on Thursday. The company has a 50-day simple moving average of $20.77 and a two-hundred day simple moving average of $20.76. The stock has a market capitalization of $13.82 billion, a price-to-earnings ratio of 12.25, a price-to-earnings-growth ratio of 7.26 and a beta of 0.96. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.56.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. On average, sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 14th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Sanford C. Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. Truist Financial decreased their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.